Neurocrine Biosciences
NBIX
#1326
Rank
A$24.55 B
Marketcap
A$244.17
Share price
2.64%
Change (1 day)
26.92%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): A$9.99

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is A$9.72. In 2025 the company made an earnings per share (EPS) of A$6.98 an increase over its 2024 EPS that were of A$4.90.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$9.9943.11%
2025A$6.9842.6%
2024A$4.9033.07%
2023A$3.6857.76%
2022A$2.3369.47%
2021A$1.38-78.21%
2020A$6.32990%
2019A$0.5881.82%
2018A$0.32-113.5%
2017A-$2.360.62%
2016A-$2.3557.28%
2015A-$1.4925.61%
2014A-$1.1918.84%
2013A-$1.00-1085.71%
2012A$0.10

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
A$1.90-80.48%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$2.98-69.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$40.90 320.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A$1.33-86.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
A-$2.94-130.25%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$5.07-47.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
A-$43.32-545.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$2.76-71.62%๐Ÿ‡ฌ๐Ÿ‡ง UK